Vivek Anand1, Madhuram Khandelwal1, Sandeep Appunni1, Nidhi Gupta1, Amlesh Seth2, Prabhjot Singh2, Sandeep Mathur3, Alpana Sharma4. 1. Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India. 2. Department of Urology, All India Institute of Medical Sciences (AIIMS), New Delhi, India. 3. Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India. 4. Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India. dralpanasharma@gmail.com.
Abstract
PURPOSE: The incidence of Urothelial carcinoma of bladder (UBC) is gradually increasing by changing lifestyle and environment. The development of a tumor has been noted to be accompanied by modifications in the extracellular matrix (ECM) consisting of CD44, hyaluronic acid (HA) and its family members. The importance of CD44 splice variants and HA family members has been studied in UBC. METHODS: The cohort of study included 50 UBC patients undergoing radical cystectomy and 50 healthy subjects. The molecular expression of CD44 and HA family members was determined. Effect of CD44 variant-specific silencing on downstream signaling in HT1376 cells was investigated. Combinatorial treatment of 4-MU (4-methylumbelliferone) with cisplatin or doxorubicin on chemosensitivity was also explored. RESULTS: Higher expression of HA, HAS2, and CD44 was observed in Indian UBC patients which also showed the trend with severity of disease. Splice variant assessment of CD44 demonstrated the distinct role of CD44v3 and CD44v6 in bladder cancer progression. shRNA-mediated downregulation of CD44v3 showed an increase effect on cell cycle, apoptosis and multiple downstream signaling cascade including pAkt, pERK and pSTAT3. Furthermore, 4-MU, an HA synthesis inhibitor, observed to complement the effect of Cisplatin or Doxorubicin by enhancing the chemosensitivity of bladder cancer cells. CONCLUSIONS: Our findings exhibit involvement of CD44 splice variants and HA family members in UBC and significance of 4-MU in enhancing chemosensitivity suggesting their novel therapeutic importance in disease therapeutics.
PURPOSE: The incidence of Urothelial carcinoma of bladder (UBC) is gradually increasing by changing lifestyle and environment. The development of a tumor has been noted to be accompanied by modifications in the extracellular matrix (ECM) consisting of CD44, hyaluronic acid (HA) and its family members. The importance of CD44 splice variants and HA family members has been studied in UBC. METHODS: The cohort of study included 50 UBCpatients undergoing radical cystectomy and 50 healthy subjects. The molecular expression of CD44 and HA family members was determined. Effect of CD44 variant-specific silencing on downstream signaling in HT1376 cells was investigated. Combinatorial treatment of 4-MU (4-methylumbelliferone) with cisplatin or doxorubicin on chemosensitivity was also explored. RESULTS: Higher expression of HA, HAS2, and CD44 was observed in Indian UBCpatients which also showed the trend with severity of disease. Splice variant assessment of CD44 demonstrated the distinct role of CD44v3 and CD44v6 in bladder cancer progression. shRNA-mediated downregulation of CD44v3 showed an increase effect on cell cycle, apoptosis and multiple downstream signaling cascade including pAkt, pERK and pSTAT3. Furthermore, 4-MU, an HA synthesis inhibitor, observed to complement the effect of Cisplatin or Doxorubicin by enhancing the chemosensitivity of bladder cancer cells. CONCLUSIONS: Our findings exhibit involvement of CD44 splice variants and HA family members in UBC and significance of 4-MU in enhancing chemosensitivity suggesting their novel therapeutic importance in disease therapeutics.
Authors: Zahra Amirghofran; Seyed Amir Jalali; Seyed Vahid Hosseini; Mohammad Vasei; Behnam Sabayan; Abbas Ghaderi Journal: J Gastrointest Cancer Date: 2009-03-31
Authors: Michael Rose; Erik Noetzel; Jennifer Kistermann; Julian Eschenbruch; Sandra Rushrush; Lin Gan; Ruth Knüchel; Nadine T Gaisa; Edgar Dahl Journal: Cells Date: 2021-04-28 Impact factor: 6.600
Authors: Sheng Wu; Katja Nitschke; Thomas Stefan Worst; Alexander Fierek; Cleo-Aron Weis; Markus Eckstein; Stefan Porubsky; Maximilian Kriegmair; Philipp Erben Journal: J Exp Clin Cancer Res Date: 2020-12-17